BrainsWay Begins Clinical Trial of Deep TMS 360 System in Alcohol Use Disorder

MT Newswires Live11-17

BrainsWay (BWAY) said Monday it has launched a multicenter clinical trial to assess its Deep TMS 360 system in people with alcohol use disorder.

The randomized, double-blind trial will enroll over 200 adults with moderate to severe AUD for about six months of active or sham treatment, with the proportion of patients reporting no heavy drinking days during the first four months of treatment as primary endpoint, the company said.

Participants will also receive behavioral and educational support during the study, BrainsWay said.

The trial will take place at multiple sites in the US, Israel, and Sweden, it added.

Shares of BrainsWay were down about 3% in recent trading Monday.

Price: 15.29, Change: -0.47, Percent Change: -2.98

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment